Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 2/20 | 0.59 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.58 |
| ▸ | CDK4 | P11802 | 1/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.58 |
| ▸ | CCND1 | P24385 | 1/20 | 0.58 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.58 |
| ▸ | FBP1 | P09467 | 1/20 | 0.53 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 3/20 | 0.47 |
| ▸ | MMP2 | P08253 | 3/20 | 0.47 |
| ▸ | MMP9 | P14780 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2348351 | 1.00 | LCK (0.59) | LCKCCNB2CDK1CDK4CCNB1 | |
| SCHEMBL13338339 | 0.80 | LCK (0.86) | LCKCCNB2CDK1CDK4CCNB1 | |
| SCHEMBL2512336 | 0.80 | LCK (0.86) | LCKCCNB2CDK1CDK4CCNB1 | |
| SCHEMBL2512334 | 0.80 | LCK (0.86) | LCKCCNB2CDK1CDK4CCNB1 | |
| SCHEMBL11046826 | 0.80 | ENPP2 (0.61) | LCKCCNB2CDK1CDK4CCNB1 | |
| SCHEMBL11046823 | 0.80 | ENPP2 (0.61) | LCKCCNB2CDK1CDK4CCNB1 | |
| SCHEMBL9163891 | 0.79 | LCK (0.59) | LCKAKR1B1ABL1BCRMMP2 | |
| SCHEMBL9163887 | 0.79 | LCK (0.59) | LCKAKR1B1ABL1BCRMMP2 | |
| SCHEMBL11033125 | 0.76 | CCNB2 (0.76) | LCKCCNB2CDK1CDK4CCNB1 | |
| SCHEMBL11044915 | 0.76 | APP (0.52) | LCKCCNB2CDK1CDK4CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090300800-A1 | D-Amino Acid a Selectable Marker for Barley (Hordeum Vulgare L.) Transformation | BASF PLANT SCIENCE GMBH (DE) | 2009-12-03 | — | — | US | claimed |
| US-20070248996-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | PARAECIS PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | US | claimed |
| US-20060014696-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | US | claimed |
| EP-0929574-B1 | MODULATORS OF beta-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | PRAECIS PHARM INC (US) | 2005-06-29 | — | — | EP | claimed |
| US-20020103134-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | PRAECIS PHARMACEUTICALS INC. | 2002-08-01 | — | — | US | claimed |
| EP-0785190-B1 | Quinolinone derivative and antiallergic agent with said quinolinone derivative as the active ingredient | DAINIPPON INK & CHEMICALS (JP) | 2000-08-16 | — | — | EP | claimed |
| US-5985242-A | PEPTIDE OF 3 TO 5 D-AMINO ACIDS; MAY BE MODIFIED AT AMINO-AND/OR CARBOXY TERMINUS; FOR TREATMENT OF AMYLOIDOSIS, ALZHEIMER'S DISEASE | PRAECIS PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | claimed |
| EP-0929574-A1 | MODULATORS OF beta-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | Praecis Pharmaceuticals Incorporated (US) | 1999-07-21 | — | — | EP | claimed |
| WO-1998008868-A9 | MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | — | 1998-05-28 | — | — | WO | claimed |
| WO-1998008868-A1 | MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 1998-03-05 | — | — | WO | claimed |
| CN-117820409-A | Oleanolic acid derivative, preparation method thereof and application thereof in resisting tumors | 沈阳药科大学 | 2024-04-05 | — | — | CN | disclosed |
| EP-2257297-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACNE, SEBORRHOEA AND SEBHORROEIC DERMATITIS, OR FOR REDUCING SEBUM SECRETION | MIMETICA PTY LTD (AU) | 2017-10-18 | — | — | EP | disclosed |
| US-9340517-B2 | Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor | MIMETICA PTY LTD (AU) | 2016-05-17 | — | — | US | disclosed |
| US-20150157621-A1 | THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND METHOD FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE USING THE SAME | MARIPOSA HEALTH LTD (AU) | 2015-06-11 | — | — | US | disclosed |
| US-8980914-B2 | Therapeutic agent for chronic obstructive pulmonary disease and method for treatment for chronic obstructive pulmonary disease with the same | MARIPOSA HEALTH LIMITED (AU) | 2015-03-17 | — | — | US | disclosed |
| WO-1998008868-A1 | MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 1998-03-05 | — | — | WO | disclosed |
| EP-0785190-A2 | Quinolinone derivative and antiallergic agent with said quinolinone derivative as the active ingredient | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1997-07-23 | — | — | EP | disclosed |
| EP-0581979-A1 | Quinic acid derivatives and process to prepare quinic acid derivatives | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 1994-02-09 | — | — | EP | disclosed |
| US-4438277-A | Hydronaphthalene derivatives | SANKYO COMPANY, LIMITED (JP) | 1984-03-20 | — | — | US | disclosed |
| US-4361515-A | Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070248996-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | APP, IAPP, BACE1 | LCK 3325/4885CCNB2 2415/4885CDK1 3801/4885 |
| US-20020103134-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | IAPP, APP, VIP | LCK 3173/4885CCNB2 2716/4885CDK1 4311/4885 |
| US-20060014696-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | APP, IAPP, BACE1 | LCK 3325/4885CCNB2 2415/4885CDK1 3801/4885 |
| US-20150157621-A1 | THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND METHOD FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE USING THE SAME | ELANE, ARG2, CFTR | LCK 3279/4885CCNB2 3797/4885CDK1 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.